Impact of Estrogen on Purinergic Signaling in Microvascular Disease
International Journal of Molecular Sciences · 27.02.2025 · 26 (5) · 2105
DOI: 10.3390/ijms26052105 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.02.2025. Verfasst von Jessica Cassavaugh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Estrogens, Signal Transduction, Microvessels, Vascular Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 207 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Anesthesia Education and Research, NIDDK NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Microvascular ischemia, especially in the heart and kidneys, is associated with inflammation and metabolic perturbation, resulting in cellular dysfunction and end-organ failure. Heightened production of adenosine from extracellular nucleotides released in response to inflammation results in protective effects, inclusive of adaptations to hypoxia, endothelial cell nitric oxide release with the regulation of vascular tone, and inhibition of platelet aggregation. Purinergic signaling is modulated by ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39, which is the dominant factor dictating vascular metabolism of extracellular ATP to adenosine throughout the cardiovascular tissues. Excess levels of extracellular purine metabolites, however, have been associated with metabolic and cardiovascular diseases. Physiological estrogen signaling is anti-inflammatory with vascular protective effects, but pharmacological replacement use in transgender and postmenopausal individuals is associated with thrombosis and other side effects. Crucially, the loss of this important sex hormone following menopause or with gender reassignment is associated with worsened pro-inflammatory states linked to increased oxidative stress, myocardial fibrosis, and, ultimately, diastolic dysfunction, also known as Yentl syndrome. While there is a growing body of knowledge on distinctive purinergic or estrogen signaling and endothelial health, much less is known about the relationships between the two signaling pathways. Continued studies of the interactions between these pathways will allow further insight into future therapeutic targets to improve the cardiovascular health of aging women without imparting deleterious side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
ORCID-Profile: Jessica Cassavaugh, Maria Serena Longhi, Simon C Robson
Förderung
- Foundation for Anesthesia Education and Research
- NIDDK NIH HHS
- NHLBI NIH HHS
- NIA NIH HHS
- Crohn's and Colitis Foundation of America - Litwin IBD Pioneers Award
- NIH HHS
- National Institutes of Health
- rohn’s and Colitis Foundation of America—Litwin IBD Pioneers Award (MSL)
Zitieren
APA
Cassavaugh, J., Longhi, M. S., & Robson, S. C. (2025). Impact of Estrogen on Purinergic Signaling in Microvascular Disease. International Journal of Molecular Sciences, 26(5), 2105. https://doi.org/10.3390/ijms26052105
Vancouver
Cassavaugh J, Longhi MS, Robson SC. Impact of Estrogen on Purinergic Signaling in Microvascular Disease. International Journal of Molecular Sciences. 2025;26(5):2105. doi:10.3390/ijms26052105
BibTeX
@article{Cassavaugh2025,
author = {Cassavaugh, Jessica and Longhi, Maria Serena and Robson, Simon C},
title = {Impact of Estrogen on Purinergic Signaling in Microvascular Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {5},
pages = {2105},
doi = {10.3390/ijms26052105}
}
EUVIMED